Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).

Published:2011-05-20 Issue:15_suppl Volume:29 Page:6500-6500
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Verstovsek S.,Mesa R. A.,Gotlib J. R.,Levy R. S.,Gupta V.,DiPersio J. F.,Catalano J.,Deininger M.,Miller C. B.,Silver R. T.,Talpaz M.,Winton E. F.,Harvey J. H.,Vaddi K.,Erickson-Viitanen S. K.,Koumenis I.,Sun W.,Sandor V.,Kantarjian H.,

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2011.29.15_suppl.6500

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis;Cancers;2021-09-28

2. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence;Science Translational Medicine;2016-04-13

3. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications;The Oncologist;2015-08-24

4. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis;Cochrane Database of Systematic Reviews;2015-04-10

5. Allogeneic Stem Cell Transplant vs. Janus Kinase Inhibition in the Treatment of Primary Myelofibrosis or Myelofibrosis After Essential Thrombocythemia or Polycythemia Vera;Clinical Lymphoma Myeloma and Leukemia;2014-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP